| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5899402 | Diabetes Research and Clinical Practice | 2014 | 8 Pages |
Abstract
Results suggest that sustained secretion of Ex-4 following dsAAV-mediated gene therapy is feasible. SGs appear to be promising targets with potential clinical applicability for the treatment of DM. This represents the example of a successful use of Ex-4 for diabetes therapy, providing support for direct AAV-mediated in vivo as an easy, safe and efficient therapeutic strategy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Junhong Wang, Feng Wang, Jing Xu, Shimei Ding, Yonghong Guo,